USA flag logo/image

An Official Website of the United States Government

THE LONG-TERM OBJECTIVE IS TO PREPARE AN EFFECTIVE LIPOSOME ENCAPSULATED…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
3017
Program Year/Program:
1985 / SBIR
Agency Tracking Number:
3017
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Biological Therapeutics, Inc.
3505 Riverview Circle Moorhead, MN 56560
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1985
Title: THE LONG-TERM OBJECTIVE IS TO PREPARE AN EFFECTIVE LIPOSOME ENCAPSULATED REAGENT WHICH WILL BE PREFERENTIALLY TARGETED TO LIVER MACROPHAGES RESULTING IN MACROPHAGE ACTIVATION FOR THE THERAPY OF METASTATIC HEPATIC DISEASE.
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THE LONG-TERM OBJECTIVE IS TO PREPARE AN EFFECTIVE LIPOSOME ENCAPSULATED REAGENT WHICH WILL BE PREFERENTIALLY TARGETED TO LIVER MACROPHAGES RESULTING IN MACROPHAGE ACTIVATION FOR THE THERAPY OF METASTATIC HEPATIC DISEASE. THE SPECIFIC AIMS ARE: 1.TO PRODUCE A LIPOPHILIC DERIVATIVE OF THE MYCOBACTERIAL CELL WALL AND INCORPORATE THAT IN LIPOSOMES DESIGNED TO BE PREFERENTIALLY TAKEN UP 2.TO DETERMINE THE TOXICITY OF THE REAGENT; 4.TO DETERMINE THE EFFECTS ON HEPATIC METASTASIS IN SEVERAL ANIMAL MODELS; AND 5.TO DETERMINE THE TOXICITY AND IMMUNOLOGICAL EFFECTS IN PHASE I AND II CLINICAL TRIALS. COMPLETION OF THIS PROJECT WILL IDENTIFY THE POTENTIAL OF THE REAGENT AND POTENTIAL COMMERCIAL VALUE. FURTHER PHASE I OR II TESTING, IF INDICATED, MAY BE DONE UNDER NCI AUSPICES, AS PART OF AN AGREEMENT WITH A PHARMACEUTICAL COMPANY OR USING VENTURE CAPITAL.

Principal Investigator:

Karl e. swenson
PRINCIPAL INVESTIGATOR
2182367648

Business Contact:

Small Business Information at Submission:

Biological Therapeutics, Inc.
3505 Riverview Circle Moorhead, MN 56560

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No